NT-II™ Collagen for Joint Discomfort and Function
← catalyst calendarSponsored by Hofseth Biocare ASA (industry) · HBC.OL — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
120estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | 2026-07-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Activity-Related Knee Discomfort
- Joint Discomfort
- Functional Joint Pain
- Functional Knee Pain
- Knee Acute and Chronic Pain
Interventions
- Dietary supplement: NT-II™ (240 mg)
- Dietary supplement: NT-II™ 480 mg
- Dietary supplement: Glucosamine/Chondroitin
Primary outcome
what the primary-completion date above is the date OFChange in participant-nominated activity-related knee discomfort (VASNA for pain) from baseline to week 12
measured Baseline to Week 12
Permalink · HBC.OL's whole pipeline · Catalyst calendar · Every registered study · What changed